{"id":"W3170518524","doi":"10.1200/jco.2021.39.15_suppl.4500","title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval","funders":"","keywords":"Medicine; Sunitinib; Interim analysis; Clinical endpoint; Renal cell carcinoma; Discontinuation; Internal medicine; Population; Temsirolimus; Randomization; Oncology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002194509,0.0005545973,0.003617002,0.0002297006,0.000137152,0.00002329014,0.0004961012,0.0009391106,0.0004454437],"category_scores_gemma":[0.00566754,0.0004408575,0.002213739,0.0003226803,0.0003355596,0.0001767662,0.0001589633,0.001560601,0.0000431282],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005997381,"about_ca_system_score_gemma":0.005498107,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002244029,"about_ca_topic_score_gemma":0.0002557334,"domain_scores_codex":[0.9913373,0.0008801839,0.005239051,0.0008192281,0.0009924518,0.0007318052],"domain_scores_gemma":[0.9790179,0.0126702,0.004321326,0.000940821,0.002093,0.0009567481],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9009506,0.007680784,0.001893085,0.0002200619,0.001333482,0.00746959,0.001051207,0.0005875072,0.01664474,0.00006130318,0.008190626,0.05391705],"study_design_scores_gemma":[0.5004011,0.1666479,0.04290229,0.0003805961,0.002197866,0.0004251132,0.001165327,0.0003772044,0.1472316,0.0005229003,0.1371141,0.0006340467],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9719769,0.003637269,0.0001453413,0.004222455,0.003508453,0.0008663725,0.0002346574,0.00002631476,0.01538224],"genre_scores_gemma":[0.9806201,0.003050898,0.009897376,0.0008380481,0.002291915,0.00002367635,0.0002387191,0.0001092817,0.002929919],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4005495,"threshold_uncertainty_score":0.9998043,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1369349574767477,"score_gpt":0.4100780355737302,"score_spread":0.2731430780969825,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}